Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Acquired by Axa S.A.

Axa S.A. increased its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 204.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 29,840 shares of the biotechnology company’s stock after purchasing an additional 20,023 shares during the quarter. Axa S.A.’s holdings in Corcept Therapeutics were worth $1,504,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Corcept Therapeutics by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 10,115,624 shares of the biotechnology company’s stock worth $509,726,000 after acquiring an additional 109,294 shares during the period. Parallel Advisors LLC grew its position in shares of Corcept Therapeutics by 0.4% during the 4th quarter. Parallel Advisors LLC now owns 3,829,632 shares of the biotechnology company’s stock valued at $192,975,000 after acquiring an additional 15,908 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in Corcept Therapeutics by 4.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,644,942 shares of the biotechnology company’s stock valued at $82,889,000 after purchasing an additional 64,321 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Corcept Therapeutics by 2.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,051,560 shares of the biotechnology company’s stock valued at $52,988,000 after purchasing an additional 25,073 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of Corcept Therapeutics by 10.2% during the fourth quarter. Northern Trust Corp now owns 1,015,515 shares of the biotechnology company’s stock worth $51,172,000 after purchasing an additional 94,128 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Stock Performance

NASDAQ CORT opened at $71.39 on Friday. Corcept Therapeutics Incorporated has a fifty-two week low of $25.35 and a fifty-two week high of $117.33. The firm has a market capitalization of $7.57 billion, a P/E ratio of 56.66 and a beta of 0.22. The stock’s fifty day moving average is $66.58 and its two-hundred day moving average is $60.64. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.17. The firm had revenue of $157.21 million during the quarter, compared to analyst estimates of $177.93 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. Corcept Therapeutics’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.25 earnings per share. On average, research analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CORT. Piper Sandler lifted their price objective on Corcept Therapeutics from $128.00 to $131.00 and gave the stock an “overweight” rating in a report on Thursday, April 3rd. HC Wainwright dropped their price target on Corcept Therapeutics from $150.00 to $145.00 and set a “buy” rating for the company in a research report on Tuesday. Canaccord Genuity Group increased their price objective on Corcept Therapeutics from $130.00 to $142.00 and gave the company a “buy” rating in a research note on Tuesday, April 1st. Truist Financial set a $135.00 target price on shares of Corcept Therapeutics in a research note on Tuesday. Finally, StockNews.com upgraded shares of Corcept Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $138.25.

Insider Buying and Selling

In related news, CEO Joseph K. Belanoff sold 2,924 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $60.91, for a total value of $178,100.84. Following the sale, the chief executive officer now directly owns 3,019,411 shares in the company, valued at approximately $183,912,324.01. The trade was a 0.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $68.08, for a total transaction of $149,776.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 236,738 shares of company stock worth $20,476,238. Company insiders own 20.80% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.